Signos, a metabolic health platform that utilizes a unique AI-engine with a continuous glucose monitor (CGM) to offer real-time data and recommendations
Signos, a metabolic health platform that utilizes a unique AI-engine with a continuous glucose monitor (CGM) to offer real-time data and recommendations for healthy weight management, has announced a successful $20 million Series B funding round.
Signos set itself the mission of addressing the obesity and metabolic health crisis that currently afflicts the United States.
With more than 96 million Americans prediabetic and an estimated 1 billion people projected to have diabetes by 2050, the company says the need for early detection and lifestyle changes is more critical than ever.
His experiences inspired him to leverage CGM technology to extend the benefits of glucose insight to a broader population, including those living with Type 2 diabetes.
“This new round of funding will allow us to expand our core team and platform and conduct additional research on metabolic health.
Hiring suitable candidates and making the Signos platform widely available, particularly with the relatively high cost of CGM technology, are key areas of focus for the company.
The original article contains 540 words, the summary contains 165 words. Saved 69%. I’m a bot and I’m open source!
This is the best summary I could come up with:
Signos, a metabolic health platform that utilizes a unique AI-engine with a continuous glucose monitor (CGM) to offer real-time data and recommendations for healthy weight management, has announced a successful $20 million Series B funding round.
Signos set itself the mission of addressing the obesity and metabolic health crisis that currently afflicts the United States.
With more than 96 million Americans prediabetic and an estimated 1 billion people projected to have diabetes by 2050, the company says the need for early detection and lifestyle changes is more critical than ever.
His experiences inspired him to leverage CGM technology to extend the benefits of glucose insight to a broader population, including those living with Type 2 diabetes.
“This new round of funding will allow us to expand our core team and platform and conduct additional research on metabolic health.
Hiring suitable candidates and making the Signos platform widely available, particularly with the relatively high cost of CGM technology, are key areas of focus for the company.
The original article contains 540 words, the summary contains 165 words. Saved 69%. I’m a bot and I’m open source!